As the list of indications for these therapies continues to expand and current market dynamics persist, these challenges will only be further exacerbated
The SELECT trial (N=17,604), which studied semaglutide 2.4 mg in patients with obesity and established cardiovascular disease (but not necessarily diabetes), reported a 20% reduction in MACE at a median follow-up of 39.8 months 9
As a primary care physician, here are the top three categories of patients that GLP-1 drugs might benefit: DOWNLOAD OUR FREE EBOOK Concierge Medicine is the future of healthcare
Many patients can safely use Mounjaro under clinician supervision
stomach emptying and gut motility go down to give you a longer feeling of fullness), in the liver (reduced glucose production
Why It Works By focusing on very low carbohydrate intake, high fat consumption, and achieving ketosis, a ketogenic approach can reduce hunger and enhance satiety.(9, 10) This aligns with the appetite-suppressing effects of GLP-1 medications, offering a natural and potentially more sustainable alternative